Brokerages Set DaVita Inc. (NYSE:DVA) Target Price at $100.43

Shares of DaVita Inc. (NYSE:DVAGet Rating) have received an average rating of “Hold” from the eight ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $100.43.

DVA has been the topic of several research reports. Barclays reduced their price target on shares of DaVita from $128.00 to $103.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 4th. Cowen cut their target price on shares of DaVita to $95.00 in a research note on Tuesday, August 9th. UBS Group increased their price target on shares of DaVita from $106.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, August 19th. Bank of America dropped their price target on shares of DaVita from $110.00 to $90.00 and set an “underperform” rating on the stock in a research note on Tuesday, June 21st. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on shares of DaVita from $150.00 to $97.00 and set a “buy” rating on the stock in a research note on Tuesday, August 2nd.

DaVita Price Performance

NYSE:DVA opened at $87.49 on Friday. The company has a debt-to-equity ratio of 11.69, a current ratio of 1.41 and a quick ratio of 1.37. The firm has a market cap of $7.99 billion, a price-to-earnings ratio of 10.85, a price-to-earnings-growth ratio of 1.42 and a beta of 1.14. The company has a 50 day moving average price of $89.00 and a 200-day moving average price of $97.20. DaVita has a 1-year low of $74.97 and a 1-year high of $124.81.

DaVita (NYSE:DVAGet Rating) last posted its earnings results on Monday, August 1st. The company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.09 by $0.21. The firm had revenue of $2.93 billion during the quarter, compared to analyst estimates of $2.93 billion. DaVita had a net margin of 7.17% and a return on equity of 84.69%. The business’s quarterly revenue was up .4% on a year-over-year basis. During the same period in the previous year, the firm earned $2.64 EPS. Equities research analysts forecast that DaVita will post 7.64 EPS for the current year.

Institutional Trading of DaVita

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Johnson Financial Group Inc. purchased a new stake in DaVita in the 4th quarter valued at about $27,000. Parkside Financial Bank & Trust grew its holdings in DaVita by 88.6% in the 1st quarter. Parkside Financial Bank & Trust now owns 313 shares of the company’s stock valued at $35,000 after buying an additional 147 shares during the period. ACG Wealth purchased a new stake in DaVita in the 2nd quarter valued at about $28,000. CWM LLC grew its holdings in DaVita by 154.1% in the 1st quarter. CWM LLC now owns 432 shares of the company’s stock valued at $49,000 after buying an additional 262 shares during the period. Finally, FourThought Financial LLC lifted its stake in shares of DaVita by 49.6% in the 1st quarter. FourThought Financial LLC now owns 510 shares of the company’s stock valued at $56,000 after purchasing an additional 169 shares in the last quarter. Hedge funds and other institutional investors own 88.47% of the company’s stock.

About DaVita

(Get Rating)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Stories

Analyst Recommendations for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.